Compounds > alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol
Page last updated: 2024-09-02

alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and racemetirosine

alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol has been researched along with racemetirosine in 1 studies

Compound Research Comparison

Studies
(alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol)		Trials
(alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol)		Recent Studies (post-2010)
(alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol)		Studies
(racemetirosine)		Trials
(racemetirosine)		Recent Studies (post-2010) (racemetirosine)
90121,1654596

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cler, JA; Iyengar, S; Oei, EJ; Rao, TS; Wood, PL1

Other Studies

1 other study(ies) available for alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and racemetirosine

ArticleYear
Increased release of dopamine in vivo by BMY-14802: contrasting pattern to clozapine.
    Neuropharmacology, 1990, Volume: 29, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Methyltyrosine; Animals; Anti-Anxiety Agents; Brain Chemistry; Clozapine; Corpus Striatum; Dibenzazepines; Dopamine; Homovanillic Acid; Male; Methyltyrosines; Mice; Olfactory Bulb; Pyrimidines

1990